Twenty early idiopathic Parkinson's disease (IPD) subjects were treated with dopamine agonist lisuride in combination with MAO-B inhibitor selegiline (L-deprenyl) and compared to a group of 31 IPD patients treated with lisuride alone. The 4 year follow-up revealed that the patients treated with lisuride plus selegiline required lower daily doses of lisuride, with both lower percentage of side-effects and loss of efficacy. Early use of combined therapy with lisuride and selegiline has a better therapeutic index than lisuride alone, possibly due to a synergistic effect between lisuride and selegiline on dopaminergic transmission. Another advantage besides reduced daily doses of lisuride can be the postponing of L-dopa therapy and related long term complications.
|Number of pages||5|
|Journal||New Trends in Clinical Neuropharmacology|
|Publication status||Published - 1992|
ASJC Scopus subject areas
- Clinical Neurology